Six, not eight cycles of bi-weekly CHOP with rituximab (RCHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the RICOVER-60 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL).

被引：0
|
作者：
Pfreundschuh, M [1 ]
Kloess, M [1 ]
Schmits, R [1 ]
Zeynalova, S [1 ]
Lengfelder, E [1 ]
Franke, A [1 ]
Steinhauer, H [1 ]
Reiser, M [1 ]
Clemens, M [1 ]
Nickenig, C [1 ]
de Wit, M [1 ]
Hoffmann, M [1 ]
Mertelsmann, R [1 ]
Metzner, B [1 ]
Ho, A [1 ]
Truemper, L [1 ]
Eimermacher, H [1 ]
Mergenthaler, H [1 ]
Liersch, R [1 ]
Duehrsen, U [1 ]
Balleisen, L [1 ]
Hartmann, F [1 ]
Poeschel, V [1 ]
Schmitz, N [1 ]
Loeffler, M [1 ]
机构：
[1] Univ Saarland, Sch Med, Med Klin 1,DSHNHl, German High Grade Non Hodgkin Lymphoma Study Grp, D-6650 Homburg, Saarland, Germany
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
13
引用
收藏
页码：9A / 9A
页数：1
相关论文
共 50 条
  • [31] Peg-filgrastim (PEG-F) on day 4 of (R-)CHOP-14 chemotherapy is superior to day 2 in elderly patients with diffuse large B-cell-lymphoma (DLBCL):: Results of a randomized trial of the German high-grade non-Hodgkin-lymphoma study group (DSHNHL)
    Poeschel, V.
    Hartmann, F.
    Zeynalova, S.
    Nickenig, C.
    Reiser, M.
    Lengfelder, E.
    Duerk, H.
    Murawski, N.
    Schubert, J.
    Loeffler, M.
    Pfreundschuh, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 149 - 149
  • [32] Aggressive Chemotherapy (CHOEP-14) and Rituximab or High-Dose Therapy (MegaCHOEP) and Rituximab for Young, High-Risk Patients with Aggressive B-Cell Lymphoma: Results of the MegaCHOEP Trial of the German High - Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
    Schmitz, Norbert
    Nickelsen, Maike
    Ziepert, Marita
    Haenel, Matthias
    Borchmann, Peter
    Viardot, Andreas
    Nickenig, Christina
    Bentz, Martin
    Peschel, Christian
    Truemper, Lorenz
    Loeffler, Markus
    Pfreundschuh, Michael
    Glass, Bertram
    BLOOD, 2009, 114 (22) : 168 - 168
  • [33] The Role of Radiotherapy to Bulky Disease in the Rituximab Era: Results from Two Prospective Trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group (DSHNHL) for Elderly Patients with DLBCL
    Pfreundschuh, Michael
    Ziepert, Marita
    Reiser, Marcel
    Poeschel, Viola
    Wilhelm, Sibylla
    Gaska, Tobias
    Heike, Michael
    Schmitz, Norbert
    Ruebe, Christian
    Loeffler, Markus
    Schubert, Joerg
    BLOOD, 2008, 112 (11) : 219 - 219
  • [34] Practicability and acute haematological toxicity of 2-and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
    Wunderlich, A
    Kloess, M
    Reiser, M
    Rudolph, C
    Truemper, L
    Bittner, S
    Schmalenberg, H
    Schmits, R
    Pfreundschuh, M
    Loeffler, M
    ANNALS OF ONCOLOGY, 2003, 14 (06) : 881 - 893
  • [35] Improved Outcome of Elderly Poor-Prognosis DLBCL Patients with 6xCHOP-14 and 8 Applications of Rituximab (R) Given Over An Extended Period: Results of the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
    Pfreundschuh, Michael
    Held, Gerhard
    Zeynalova, Samira
    Poeschel, Viola
    Viardot, Andreas
    Haenel, Matthias
    Keller, Ulrich
    Reiser, Marcel
    Loeffler, Markus
    Murawski, Niels
    BLOOD, 2011, 118 (21) : 272 - 273
  • [36] Clinical relevance of genomic aberrations in diffuse large B-cell lymphoma -: An analysis within a multicentric treatment trial of the German High Grade Lymphoma Study Group (DSHNHL).
    Bentz, M
    Kloess, M
    Baudis, M
    Feller, AC
    Ott, G
    Enz, M
    Trümper, LH
    Pfreundschuh, M
    Lichter, P
    Döhner, H
    BLOOD, 2001, 98 (11) : 464A - 464A
  • [37] Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma:: II.: Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
    Pfreundschuh, M.
    Zwick, C.
    Zeynalova, S.
    Duehrsen, U.
    Ger, K. -H. Pflu
    Vrieling, T.
    Mesters, R.
    Mergenthaler, H. -G.
    Einsele, H.
    Bentz, M.
    Lengfelder, E.
    Truemper, L.
    Ruebe, C.
    Schmitz, N.
    Loeffler, M.
    ANNALS OF ONCOLOGY, 2008, 19 (03) : 545 - 552
  • [38] The Impact of Radiotherapy to Bulky Disease after R-CHOP Chemotherapy in Aggressive Lymphoma: Results from Two Prospective Trials of the German High-grade Non-Hodgkin-Lymphoma Study Group (DSHNHL) for Elderly Patients with DLBCL
    Rube, C.
    Ziepert, M.
    Schmidberger, H.
    Poeschel, V.
    Mueller, R.
    Sautter-Bihl, M.
    Fritz, P.
    Loeffler, M.
    Pfreundschuh, M.
    Fleckenstein, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S63 - S63
  • [39] High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
    Nickelsen, M.
    Ziepert, M.
    Zeynalova, S.
    Glass, B.
    Metzner, B.
    Leithaeuser, M.
    Mueller-Hermelink, H. K.
    Pfreundschuh, M.
    Schmitz, N.
    ANNALS OF ONCOLOGY, 2009, 20 (12) : 1977 - 1984
  • [40] CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group
    Schmitz, N.
    Zeynalova, S.
    Glass, B.
    Kaiser, U.
    Cavallin-Stahl, E.
    Wolf, M.
    Haenel, M.
    Loeffler, M.
    Truemper, L.
    Pfreundschuh, M.
    ANNALS OF ONCOLOGY, 2012, 23 (05) : 1267 - 1273
12345